Aspire Biopharma Holdings, Inc. 8-K

What Happened
Aspire Biopharma Holdings, Inc. (ASBP) filed a Form 8‑K on February 6, 2026 (Item 5.03) to amend its Certificate of Incorporation to establish a Series A Convertible Non‑Voting Preferred Stock. The company furnished a Certificate of Designations describing the preferences, rights and limitations of the Series A preferred as Exhibit 3.1 to the 8‑K (also noted under Item 9.01).

Key Details

• Filing date: February 6, 2026 (Form 8‑K).
• Item reporting: 5.03 (Amendments to Articles of Incorporation or Bylaws).
• Exhibit: 3.1 — Certificate of Designations for the Series A Convertible Non‑Voting Preferred Stock.
• The filing creates/designates a new series of convertible, non‑voting preferred shares; the Certificate of Designations sets out the specific preferences, rights and limitations (see Exhibit 3.1 for details).

Why It Matters
This amendment changes Aspire Biopharma’s capital structure by adding a new class of convertible preferred stock. Such a series can affect common shareholders through potential conversion and dilution and may change priority in rights and liquidations. Retail investors should review the Certificate of Designations (Exhibit 3.1) to understand conversion terms, dividend rights, voting limitations and any protective provisions, and watch for future filings disclosing any issuance, pricing or holder identities.